Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Ionis Pharmaceuticals, Inc. - Common Stock (NQ:IONS)

28.19 -2.81 (-9.06%)
Official Closing Price Updated: 4:15 PM EST, Nov 10, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Ionis Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
11 12 Next >
News headline image
Ionis: 3 Key Takeaways for Long-Term Investors ↗
Ionis's $1.9 billion cash pile buys time, but it is still to be seen whether patient switches to DAWNZERA can offset a slower TRYNGOLZA launch. 
Via The Motley Fool
Topics Earnings
News headline image
Ionis (IONS) Q3 2026 Earnings Call Transcript ↗
Launch ramp slows and cash flow breakeven shifts a year to 2029. 
Via The Motley Fool
Topics Earnings
News headline image
What Ionis Pharmaceuticals (IONS) Said on Its Q3 Earnings Call ↗
Ionis Pharmaceuticals (NASDAQ:IONS) lowered its 2026 sales forecast for TRYNGOLZA after a slower-than-expected launch in severe hypertriglyceridemia, while pushing its target for sustained positive... 
Via MarketBeat
Topics Earnings
Ionis Pharmaceuticals (NASDAQ:IONS) Surges After Q2 Earnings Beat Estimates ↗
Via Chartmill
Topics Earnings
US Gap-Up and Gap-Down Movers for the Nov. 9, 2026 Session ↗
Via Chartmill
Premarket Movers on Nov. 9, 2026: Small-Cap Gainers and Losers ↗
Via Chartmill
News headline image
Alnylam Is Now Solidly Profitable. Why Are Investors Treating It Like a Broken Biotech? ↗
This beaten-down biotech has a better story than its stock chart suggests. 
Via The Motley Fool
News headline image
Alnylam vs. Ionis: Here's the Better Bad-News Buy ↗
The sell-offs for both of these beaten-down biotech stocks appear to be overdone. 
Via The Motley Fool
News headline image
18 of 21 Analysts Still Think Alnylam Stock Is a Buy. Here's Why They're Right. ↗
Wall Street expects an even bigger rebound for this beaten-down biotech stock. 
Via The Motley Fool
News headline image
Investors Dumped Ionis Pharmaceuticals Stock -- But Wall Street Hasn't Budged From Its Bullish Outlook ↗
Shares of Ionis are down more than 40% so far this year. 
Via The Motley Fool
News headline image
Ionis Pharmaceuticals Eyes TRYNGOLZA Growth as Pipeline Faces Cardio Setbacks ↗
Ionis Pharmaceuticals (NASDAQ:IONS) CEO Brett Monia outlined recent regulatory wins, commercial-launch progress and several pipeline updates at the Morgan Stanley Global Healthcare Conference, while... 
Via MarketBeat
News headline image
Novartis Just Shook Up a Multibillion-Dollar Drug Race. What It Means for Eli Lilly Stock. ↗
Lilly may be impacted by Novartis' pelacarsen flop -- but not by much. 
Via The Motley Fool
News headline image
Cathie Wood Is Loading Up on Ionis Pharmaceuticals (IONS) Stock. Here's the Bet She's Making. ↗
Ionis Pharmaceuticals is promising in multiple ways -- but it's not dirt cheap or without risks. 
Via The Motley Fool
Stay updated with the stocks that are on the move in today's after-hours session. ↗
Via Chartmill
News headline image
Ionis Pharmaceuticals Wins FDA Approval for First Alexander Disease Treatment ↗
Ionis Pharmaceuticals (NASDAQ:IONS) said the U.S. Food and Drug Administration has approved ZANVASTRO as the first and only disease-modifying treatment for Alexander disease, an ultra-rare, progressive... 
Via MarketBeat
News headline image
Here's Why Ionis Pharmaceuticals' Steep Sell-off Was Overdone ↗
This biotech stock looks like a great candidate to buy on the admittedly steep dip. 
Via The Motley Fool
News headline image
Breakfast News: A Conversation With Ionis CEO ↗
Ionis Pharmaceuticals CEO on a major profitability milestone, breakthrough medicines and more. 
Via The Motley Fool
Topics ETFs World Trade
News headline image
Why the Alnylam Sell-Off Looks Overdone -- and What Investors Are Missing ↗
Yes, Alnylam has had some bad news. But the bad news isn't as horrible as many think. 
Via The Motley Fool
News headline image
Ionis Stock Has Plunged 30%. Is It Time to Buy the Beaten-Down Stock? ↗
A drug that didn't meet expectations in a trial is to blame. 
Via The Motley Fool
News headline image
Ionis (IONS) Q2 2026 Earnings Call Transcript ↗
Revenue hit $268 million with 56% growth, while TRYNGOLZA sales accelerated. 
Via The Motley Fool
Topics Earnings
News headline image
Ionis Pharmaceuticals Director Hayden Buys $1.1 Million Shares. What Does This Mean for Investors? ↗
Insider holdings surged 34% through indirect acquisition, signaling confidence amid company's $8.8 billion valuation and RNA-therapy pipeline advancement. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Ionis Pharmaceuticals Q2 Earnings Call Highlights ↗
Ionis Pharmaceuticals (NASDAQ:IONS) reported second-quarter revenue growth driven by commercial products and partnered research programs, while highlighting the recent U.S. approval and early launch... 
Via MarketBeat
Topics Earnings
News headline image
Cathie Wood Just Bet Big on This Biotech Stock ↗
Ionis Pharmaceuticals' shares are down more than 27% so far this year. What does Cathie Wood see that others are missing? 
Via The Motley Fool
Topics ETFs
News headline image
The Phase 3 Failure That Sent Biotech Winners and Losers in Opposite Directions ↗
Wainua missed its Phase 3 endpoint, hitting Ionis Pharmaceuticals hard while AstraZeneca absorbed the blow easily, boosting rivals BridgeBio, Pfizer and Alnylam Pharmaceuticals. 
Via MarketBeat
Which stocks are experiencing notable movement on Thursday? ↗
Via Chartmill
Let's take a look at the stocks that are in motion in today's session. ↗
Via Chartmill
There are notable gap-ups and gap-downs in today's session. ↗
Via Chartmill
Discover the top movers in Thursday's pre-market session. ↗
Via Chartmill
News headline image
QURE Was Just the Beginning: 5 Biotech Catalysts I’m Watching Now ↗
Mornings like we had on Wednesday are exactly why I get up and do this show every single day the market is open. UniQure NV (QURE) opened around $43. Touched $48.88 intraday. Closed in the high $47s.... 
Via InvestorPlace
News headline image
This $5.5 Million Exit Raises Questions After Wave Life Sciences' Rough First Quarter ↗
This clinical-stage biotech develops precision genetic medicines for neurological and hepatic disorders via its PRISM platform. 
Via The Motley Fool
Topics Regulatory Compliance
< Previous 1 2 3 4 5 6 7 8 9
...
11 12 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.